U.S. Specialty Stores Stock News

Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile. See our latest analysis for Edgewise Therapeutics. Recent trading has been choppy, with a 1 day share price return of 1.12% and a 7 day share price return of an 8.28% decline. However, momentum over the past 90 days and year to date remains positive, supported by a 1 year total shareholder return...

Atomera Incorporated recently announced it has expanded its long-running collaboration with Synopsys to develop gallium nitride (GaN) device modeling workflows for radio frequency and power semiconductor applications using Synopsys’ Sentaurus TCAD and Atomera’s MSTcad toolset. This move extends Atomera’s MST modeling capabilities into GaN, potentially deepening its role in high-value RF and power markets by integrating more tightly into Synopsys’ widely used design ecosystem. We’ll now...

Evolv Technologies Holdings, Inc. recently announced multi-year subscription agreements and marketing partnerships with the University of Washington’s athletic department and Crypto.com Arena, expanding deployments of its Evolv Express Gen2 and eXpedite AI-based screening systems across major college and professional sports venues. These high-traffic stadium and arena wins highlight growing adoption of Evolv’s subscription-based security platforms in sports and entertainment, reinforcing its...

The American Academy of Dermatology’s new pediatric guidelines give a strong, evidence-backed endorsement to Arcutis Biotherapeutics (ARQT) lead product ZORYVE for children with mild to moderate atopic dermatitis, highlighting efficacy, safety, and long-term use. See our latest analysis for Arcutis Biotherapeutics. At a share price of $23.26, Arcutis has a 1 day share price return of 1.75%, while the year to date share price return of 19.79% decline contrasts with a 1 year total shareholder...

Recent performance and context for W.W. Grainger W.W. Grainger (GWW) has drawn fresh investor attention after recent share price moves, with the stock showing mixed short term returns but positive performance over the month and the past 3 months. See our latest analysis for W.W. Grainger. Recent trading has been slightly softer, with a 1-day share price return of 1.45% and a 7-day share price return of 1.29%. That sits against a 30-day share price return of 6.7% and a 1-year total shareholder...

Recent share performance and business snapshot Lucky Strike Entertainment (LUCK) has drawn attention after a recent pullback, with the share price closing at US$7.24 as investors reassess the business following its rebrand from Bowlero Corp. The company runs a portfolio of bowling centers and entertainment venues across North America, including AMF, Bowl America, Lucky Strike, Bowlero, Octane Raceway, several water parks, and Boomers Parks. It has reported revenue of US$1,240.203 million and...

SkyWest (SKYW) has kicked off Q1 2026 with total revenue of US$1.0b, basic EPS of US$2.54 and net income of US$101.7 million, setting the tone for its latest set of results. The company has seen quarterly revenue move from US$948.5 million in Q1 2025 to US$1.0b in Q1 2026, while basic EPS has shifted from US$2.48 to US$2.54 over the same period, against a backdrop of trailing 12 month EPS of US$10.69 and net income of US$429.5 million. With a trailing net margin of 10.4% versus 9.9% the prior...

Wondering if Atlas Energy Solutions at around US$16.31 offers good value for your money? This article focuses on what the current share price might mean for long-term investors. The stock has shown sharp recent moves, with returns of 22.7% over 7 days, 20.3% over 30 days, 67.8% year to date and 19.1% over the past year. These figures can change how you think about both potential upside and risk. Recent coverage has centered on Atlas Energy Solutions as investors reassess US energy services...

Why Caris Life Sciences Is On Investors’ Radar Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but showing a roughly 19% decline over the past 3 months. See our latest analysis for Caris Life Sciences. The recent 10.2% 30 day share price return stands against a 19.2% 90 day decline and a 25.1% year to date share price fall, indicating fading momentum despite the latest move. If Caris’s recent swings have...

A new product liability lawsuit alleges a design flaw in Newell Brands' CrockPot Express Crock Multicooker led to severe burn injuries when the lid opened while still under pressure. The case targets Newell Brands, listed as NasdaqGS:NWL, and focuses on product safety controls and consumer protection around its popular small appliance line. Newell Brands, through its CrockPot range, is a familiar name in many kitchens, so any allegation around product safety can quickly draw attention from...

Why Callaway Golf (CALY) Is Back in Focus Callaway Golf (CALY) is on investors’ radar after a recent name change from Topgolf Callaway Brands Corp. This shift has refocused attention on its core golf equipment and apparel business and how that mix supports current valuation. See our latest analysis for Callaway Golf. The share price at US$15.31 reflects a strong year to date share price return of 30.63%, while the 128.17% total shareholder return over one year contrasts with weaker three and...

AtaiBeckley reported detailed Phase 2a data for its oral R-MDMA candidate EMP-01 in adults with Social Anxiety Disorder. The trial showed strong and consistent efficacy, with meaningful improvements in clinician- and patient-reported symptoms and real world behavioral outcomes. EMP-01 was found to be safe and well tolerated, with high participant retention and no serious adverse events, and the results were achieved without adjunctive psychotherapy. For AtaiBeckley, listed on NasdaqGM:ATAI,...

Amneal Pharmaceuticals (NasdaqGS:AMRX) has agreed to acquire Kashiv BioSciences, creating a fully integrated global biosimilars platform. The transaction is expected to accelerate Amneal's biosimilar pipeline and support multiple planned biosimilar launches over the coming years. The combination brings together Kashiv's development capabilities with Amneal's commercial infrastructure and established generics franchise. Amneal Pharmaceuticals, trading at around $12.52, has seen a very large...

As you might know, FirstCash Holdings, Inc. ( NASDAQ:FCFS ) just kicked off its latest quarterly results with some very...

Quite a few Sono-Tek Corporation ( NASDAQ:SOTK ) insiders sold their shares over the past year, which may be a cause...

If you are wondering whether Argan's share price now reflects its true worth, the recent numbers give you plenty to think about. The stock last closed at US$652.99, with returns of 9.2% over 7 days, 49.3% over 30 days, 100.3% year to date, 333.3% over 1 year and a very large gain over 3 and 5 years. Recent coverage has focused on Argan's position within the construction and capital goods space and how the company is exposed to large infrastructure and engineering projects. This news has...

Wondering whether Trump Media & Technology Group at US$9.35 reflects the real value of the business, or if the price has drifted away from fundamentals. The stock has been volatile recently, with a 7 day return of an 8.9% decline, a 30 day return of 1.7%, and a year to date return of a 32.1% decline that contributes to a 1 year return of a 64.2% decline. These moves have played out against a backdrop of ongoing attention around the company as a media and technology platform associated with...

Nexa Resources (NYSE:NEXA) has released its 2025 Sustainability Report, outlining corporate responsibility initiatives across its mining operations, workforce, and host communities. The report details current environmental, social, and governance practices, as well as progress against existing commitments. This disclosure adds fresh ESG information for investors beyond recent share price moves and earnings-related updates. Nexa Resources, trading at $14.43, has seen a 43.4% return over the...

Tesla (TSLA) opened 2026 with Q1 revenue of US$22.4b and basic EPS of US$0.15, setting the tone against a trailing twelve month backdrop where revenue sits at US$97.9b and EPS at US$1.20. Over recent quarters, revenue has moved from US$19,335 million in Q1 2025 to US$22,387 million in Q1 2026, while basic EPS has ranged from US$0.13 to US$0.43 across 2025. This gives investors a clear view of how the top line and per share earnings are tracking into the new year. With trailing net profit...

Market context and recent share performance Netskope (NTSK) has drawn attention after recent trading, with the share price at US$9.63 and short term returns mixed, including a 1 day move of about a 1.6% decline and a 7 day decline of 2.4%. Over the past month, the stock shows a 13.6% gain, while the past 3 months reflect about a 37% decline and a year to date decline of around 43%. This keeps investor focus on how current pricing relates to the company’s fundamentals. See our latest analysis...

Mobileye Global (MBLY) opened 2026 with Q1 revenue of US$558 million and a basic EPS loss of US$4.67, while trailing twelve month figures show revenue of US$2.0 billion and a net loss of US$4.1 billion. Over the past year, the company has seen quarterly revenue move from US$438 million in Q1 2025 to US$558 million in Q1 2026, alongside basic EPS moving from a loss of US$0.13 to a much deeper loss of US$4.67. This puts the spotlight firmly on how margins are holding up against growth...

Earlier this week, Dianthus Therapeutics reported that the FDA removed antinuclear antibody screening and routine ANA testing requirements from its claseprubart clinical trials, following a safety review, while the company continues preparations to start a Phase 3 study in generalized myasthenia gravis in mid-2026 with topline data expected in the second half of 2028. This easing of trial monitoring, alongside an analyst reaffirming an Outperform rating, highlights growing regulatory and...

Some investors may be wondering whether Credicorp's current share price still offers value after a strong run, or whether most of the upside has already been captured. The stock closed at US$323.65, with a 2.5% decline over the last 7 days and a 4.5% decline over the last 30 days, set against a 13.0% year-to-date return and a 72.8% return over the last year. Recent coverage has focused on Credicorp's share price performance and how investors are reassessing risk and potential reward in light...

Columbia Banking System (COLB) opened 2026 with Q1 revenue of US$649 million and basic EPS of US$0.66, alongside trailing twelve month revenue of about US$2.3 billion and EPS of US$2.53 that reflect the earnings run rate coming into the quarter. Over recent periods, revenue has moved from US$459 million in Q4 2024 to US$694 million in Q4 2025 and US$649 million in Q1 2026, while quarterly EPS has ranged from US$0.41 in Q1 2025 to US$0.73 in Q2 2025 before landing at US$0.66 this quarter. This...